You just read:

Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients

News provided by

Synthetic Biologics, Inc.

Jan 07, 2020, 07:00 ET